4 of 13/D

In the Claims:

1. (currently amended) A method of treating a living body having a primary tumor and a metastatic tumor, said method comprising:

identifying a primary tumor tissue site of the living body;

combining an administration of an immunologic adjuvant at a predetermined concentration to said body, said predetermined concentration being ~~approximately~~ a standard concentration for immunization procedures of said body, said administered immunologic adjuvant resulting in a systemic condition of heightened nonspecific enhanced immune system of the body, including an increased level of nonspecific immune-related molecular and cellular factors and cells, with a previous administration of a photodynamic light therapy ~~proximate said primary tumor tissue site~~, said photodynamic light therapy being proximate to said primary tumor tissue site and having a light wavelength and a sufficient light dosage to eradicate tumor cells within the primary tumor tissue site, said eradicated primary tumor tissue site cells releasing necrosis-related tumor cell specific antigens as a result of the photodynamic light therapy; and

promoting and enhancing a systemic immunologic response of said body as a result of an interaction between the increased level of nonspecific immune-related molecular and cellular factors and cells and photodynamic light therapy released tumor cell specific antigens, said systemic immunologic response yielding increased levels of tumor cell specific antibodies and ~~other~~ immunologic anti-tumor cell specific products and cells for eradicating cells of the metastatic tumor.

D1

2. (original) The method of claim 1 wherein the light wavelength ranges from about 400 nm to about 800 nm, the light dosage ranges from about 10 J/cm^2 to about 250 J/cm^2 and a light dosage rate ranges from about 50 mw/cm^2 to about 200 mw/cm^2.

3. (original) The method of claim 1 wherein the wavelength ranges from about 300 nm to about 700 nm.

4. Canceled.

5. The method of claim 1 wherein the step of administering the photodynamic light therapy includes the step of administering a photosensitizing agent.

6. Canceled.

7. (currently amended) The method of claim 1 wherein the immunologic adjuvant is DETOX brand adjuvant.

8. (currently amended) The method of claim 7 wherein the DETOX brand adjuvant is administered at a 10% full strength concentration.

9. (original) The method of claim 1 wherein the administration of the immunologic adjuvant precedes the administration of the photodynamic light therapy.

10. (original) The method of claim 1 wherein the administration of the photodynamic light therapy precedes the administration of the immunologic adjuvant.

11. Canceled.

12. (original) The method of claim 1 wherein the administration of the immunologic adjuvant includes one or more separate administrations of the adjuvant to the body.

13. (original) The method of claim 1 wherein the administration of the immunologic adjuvant includes administrations before and after the administration of the photodynamic light therapy.

14. (previously amended) The method of claim 1 further comprising the step of:

administering an immune modulator to the body after the administration of photodynamic light therapy.

15. The method of claim 14 wherein the immune modulator is administered at multiple times to the body.

16 – 44. Canceled.

45. (currently amended) A method of treating a living body having a primary tumor and a metastatic tumor, said method comprising:

identifying a primary tumor tissue site of the living body;

administering a photodynamic light therapy proximate to said primary tumor tissue site, said photodynamic light therapy having a light wavelength and a sufficient light dosage to eradicate tumor cells within the primary tumor tissue site, said eradicated primary tumor tissue site cells releasing necrosis-related tumor cell specific antigens as a result of the photodynamic light therapy;

administering an immunologic adjuvant at a predetermined concentration to said body, said predetermined concentration being ~~approximately~~ a standard concentration for immunization procedures of said body, said administered immunologic adjuvant resulting in a systemic condition of heightened nonspecific enhanced immune system of the body, including an increased level of nonspecific immune-related macrophage cells; and

promoting and enhancing a systemic immunologic response of said body as a result of an interaction between the increased level of nonspecific immune-related macrophage cells and photodynamic light therapy released tumor cell specific antigens, said systemic immunologic response yielding increased levels of tumor cell specific antibodies and ~~other~~ immunologic anti-tumor cell specific products and cells for eradicating cells of the metastatic tumor resulting in a decrease in metastatic tumor size.